Singapore's EDDC and tech firm ink deal for robotics and large language models

Potential projects will focus on the application of large language models in pharmaceutical research.

Singapore's national drug platform for the Experimental Drug Development Centre (EDDC) signed a memorandum of understanding (MOU) with XtalPi to collaborate on potential projects regarding large language models in pharma research.

This partnership seeks to speed up the "conversion of scientific discoveries into robust pipeline assets by advancing the domain of intelligent automated pharmaceutical research."

Under the MOU, the two will explore collaborations in the fields of automated chemical compound synthesis and AI-driven drug discovery, including the application of XtalPi's robotics and AI-driven drug design capabilities in EDDC's R&D, such as automated library synthesis and other drug chemical synthesis services.

XtalPi's automated workstations can provide remote support to EDDC's R&D efforts, generating large-scale, high-quality data that can boost EDDC's current drug development processes. By developing cutting-edge computational tools and industry practices, the partners will leverage robotics and AI in therapeutic discovery.

The collaboration will build upon their ongoing cooperation in December 2022 where they use AI and automation to develop targeted therapies for non-small cell lung cancer.